• QuantHealth

  Participated · Series B · Aug 2026

  QuantHealth offers an AI-driven clinical trial simulation platform that enables life sciences companies to evaluate, optimize, and de-risk clinical and commercial decisions before enrolling patients or committing capital. The company serves pharmaceutical and biotechnology organizations and is led by CEO Orr Inbar. QuantHealth is based in Tel Aviv, Israel. Following its Series B, the company plans to scale enterprise-wide impact, accelerate adoption of simulation-first clinical development, advance R&D capabilities, grow its workforce, and expand its product portfolio. The article does not disclose revenues, user counts, or prior funding rounds.

• 9amHealth

  Participated · Series B · May 2026

  Founded in 2021 and headquartered in San Diego, 9amHealth provides AI-enabled virtual specialty care for conditions such as obesity, diabetes, hypertension, and dyslipidemia. The company offers an integrated model combining specialized clinicians (including endocrinologists and obesity medicine specialists), at-home lab testing, medication management, and continuous care. 9amHealth partners with employers, health plans, and pharmacy benefit managers and reports more than $50 million in projected medical and pharmacy savings across two Fortune 100 employers. It has delivered pharmacy cost savings amid rising demand for GLP-1 therapies while improving engagement and clinical outcomes. Backed by investors including Define Ventures, SemperVirens VC, 7Wire Ventures, and The Cigna Group Ventures, the company plans to expand its platform to manage a broader set of high-cost, specialty-level chronic conditions.

• Lin Health

  Participated · Series A · Dec 2025

  Founded in 2021, Denver-based Lin Health offers a physician-led, coach-supported virtual program that retrains maladaptive pain circuits through therapies such as Pain Reprocessing Therapy, Emotional Awareness and Expression Therapy, and Cognitive Behavioral Therapy. The platform combines proprietary software, AI, and a collaborative care model to engage patients multiple times per week without adding administrative burden. Lin partners with health systems, clinics, and payers and is already accessible to more than 60 million covered Americans. Its solution targets chronic conditions including migraines, IBS, back pain, and joint pain, addressing a $635 billion annual cost burden in the U.S. healthcare system. The company emphasizes value-based outcomes, reduced provider burnout, and lower total cost of care. With fresh Series A capital, Lin plans to accelerate product innovation, scale go-to-market efforts, and deepen clinically integrated partnerships. The oversubscribed funding signals strong investor confidence in Lin’s ability to become the first-line solution for chronic pain nationwide.

No current team members are available.